The following chart shows the share of the total population that has been fully vaccinated against COVID This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same.
If they receive the second dose, the metric goes up by 1. The following chart shows the total number of people that have been fully vaccinated against COVID This represents the number that have received all doses prescribed by the vaccination protocol.
The following charts show the number of booster doses administered. The following charts provide data on the share of people that have been vaccinated against COVID by age group. This is provided as three metrics: the share that have received at least one dose; the share that have been fully vaccinated; and the share that are only partly vaccinated.
Some of this data is only available for countries which report the breakdown of doses administered by first and second doses by age. The following chart shows the share of the population in each age group that have received at least one dose of the COVID vaccine.
This metric includes those that are either partly or fully vaccinated. The following chart shows the share of the population in each age group that are fully vaccinated against COVID The following chart shows the share of the population in each age group that are only partly vaccinated against COVID For a two-dose vaccine schedule, this would be people that have received only one dose. Those who are fully vaccinated are not included.
This means this metric will decrease as people receive their second dose. The following chart shows the cumulative number of doses administered, broken down by vaccine manufacturer. This is only available for a select number of countries which report the necessary data. These charts show the cumulative number of doses donated to the COVAX initiative by different countries, broken down by whether the donations have only been announced, actually donated, or delivered to the recipients.
Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated. The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.
The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset. OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.
The following two charts show monthly data from this survey on the willingness of people to get vaccinated against COVID The first chart shows this data for a single country over time, while the second chart shows the same data for multiple countries at a single point in time. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine.
The development of a vaccine against COVID has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries. This will be important because eventually a very large share of the world population needs to receive a COVID vaccine. Several institutions maintain websites on which they list COVID candidate vaccines that are currently being developed:.
You can download the full dataset alongside the detailed sources on GitHub. In some cases, the vaccination figures on this page can look different from the ones reported by a government. Most often it is not because of the numerator number of people vaccinated but instead because of the denominator number of people in the population.
This usually happens for two main reasons:. We use this data for its reliability, its consistent methods, and because it makes our work much easier. The exact values can be viewed in our GitHub repository.
The United Nations estimates may not always reflect the latest censuses or national figures—but there are several reasons why we use this data over country-by-country national population estimates. In a few cases, we use other sources when the figures provided by the UN differ substantially from reliable and more recent national estimates. The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. In our data, fully-vaccinated people are those who have received all doses prescribed by their vaccination regimen e.
Some countries also allow for alternative definitions, such as having been infected with SARS-CoV-2 in the past and having received 1 dose of a two-dose regimen.
We currently ignore these alternative definitions to preserve the common definition of fully vaccinated, i. This allows for an optimal comparability between countries. The income groups we use come from the World Bank income classification. The exact list of countries can be viewed in our GitHub repository.
Due to the limited space on our charts and the number of countries in the world, we unfortunately cannot show every country in the world by default. On each chart of this page, we therefore choose a default selection of countries based on a mix of criteria: mainly total population, but also number of vaccine doses administered and share of the population vaccinated.
These lists are updated about once a month. In the future, we plan to develop new features that would allow the list of countries to automatically adapt to the region of each visitor, and if they allow it, to use cookies to save their default list on their computer.
Because some countries — notably China, as of August — do not report breakdowns between first and second doses administered, we cannot know the exact number of people with at least 1 dose and people fully vaccinated in the world. Therefore, as long as some countries are only reporting partial data, these figures will underestimate the real number of people vaccinated and fully vaccinated globally. Based on the number of doses administered, it is however possible to calculate a lower and upper bound of how many people have been vaccinated in these countries.
For example, if million doses have been used in China, they must have been administered to at least million people with 2 doses each , and up to million people with only 1 dose each. Other countries that are not shown in our data may have also started vaccination campaigns. We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.
The vaccination data is needed to understand how the pandemic is evolving. Global health institutions that report on the pandemic are reporting these metrics separately:. Reporting the data for Palestine and Israel separately also allows us to show their respective reported vaccination levels.
They create immunity to the parts of the germ that cause a disease instead of the germ itself. That means the immune response is targeted to the toxin instead of the whole germ. Like some other types of vaccines, you may need booster shots to get ongoing protection against diseases.
For decades, scientists studied viral vector vaccines. Some vaccines recently used for Ebola outbreaks have used viral vector technology, and a number of studies have focused on viral vector vaccines against other infectious diseases such as Zika, flu, and HIV. Viral vector vaccines use a modified version of a different virus as a vector to deliver protection. Several different viruses have been used as vectors, including influenza, vesicular stomatitis virus VSV , measles virus, and adenovirus, which causes the common cold.
Adenovirus is one of the viral vectors used in some COVID vaccines being studied in clinical trials. Viral vector vaccines are used to protect against:.
Did you know that scientists are still working to create new types of vaccines? Here are 2 exciting examples:. Getting vaccinated is easy.
See how vaccines are developed, approved, and monitored. The vaccine currently being used for unders in the UK is Pfizer-BioNTech, but the Moderna vaccine has also been authorised for use in children.
Those eligible for boosters will receive one dose of Pfizer or half a dose of Moderna. There is no vaccine currently approved for use in the unders. While uptake of first and second doses has dropped off, there has been a steep rise in people having booster shots.
Boosters are being offered to frontline medical staff, overs and people who are clinically vulnerable across the UK. More than 11 million of these doses have been administered across the UK. Progress made in the UK so far means the country continues to be among those with the highest vaccination rates globally - but it has slipped out of the top 10 countries with a population of at least one million.
Vaccination rates have now levelled off in every age group in England apart from the youngest bands, as the chart below shows. The highest rates of vaccination can be seen in the oldest age groups - among the first to be vaccinated.
The aim of the vaccination programme is to protect as many people as possible from serious illness through developing the UK population's immunity against Covid Data from the Office for National Statistics ONS suggests more than nine in 10 adults in the UK now have coronavirus antibodies - which is evidence of a past Covid infection or having received at least one dose of a vaccine.
However, this figure does not tell us how many people are protected from infection or how close we are to reaching herd immunity - the point at which everyone is protected, directly or indirectly, as a result of high immunity levels in the population. Across the country, there continues to be some variation in the vaccine programme.
There have also been disparities between ethnic groups and poorer and wealthier areas. The study was based on more than 20 million patient records in England and covers people not living in care homes. Areas of London are under-represented in the data. In addition, vaccine take-up in poorer areas is lower than in more affluent areas. A second vaccine, from Oxford University and AstraZeneca, is being made at a number of sites in Britain.
The UK is also lined up to receive another vaccine if approved for use. The UK had ordered more than million doses of seven of the most promising vaccines, including the four so far approved for use.
But the French vaccine maker Valneva says the UK government has scrapped a deal for m doses of its vaccine, which is yet to be approved. An extra 35 million doses of the Pfizer-BioNTech vaccine were ordered in August, on top of another 60 million ordered earlier in the year, as part of the government's plans for a vaccination booster programme. But it has amended its original order of the Janssen single-dose vaccine from 30 million to 20 million doses, given the "unprecedented scale and pace" of the vaccination programme.
Ministers have also announced an eighth deal with biopharmaceutical company CureVac to develop vaccines against future variants.
0コメント